Archived AES Symposia 2005
AED Pharmacology - Application to Practice
Program Length: 1 hrs 44 min
This symposium will address the significant roles that the mechanisms of action and pharmacokinetics (PK) of antiepileptic drugs (AEDs) play with regard to efficacy and safety. The symposium begins with a synopsis and categorization of the mechanisms of action of AEDs. Next, pharmacokinetic characteristics of AEDs will be addressed, with basic PK parameters and their role in AED dosing, efficacy, and safety described. Finally, specific modes of drug-drug interactions and the potential influence of pharmacogenetics on efficacy, tolerability, and safety are discussed.
At the conclusion of this activity, participants should be able to:
- Evaluate the core mechanisms of action of AEDs and their potential relationship to individual therapeutic responses
- Recognize basic pharmacokinetic characteristics of AEDs as they contribute to dosing, efficacy, safety, and drug interactions in patients
- Assess the impact of pharmacogenetics on metabolism and evaluate potential sequelae of altered PK and drug interactions.
Neurologists, nurses, and pharmacists involved with the care of people with epilepsy.
Chair: Gail D. Anderson, Ph.D.
This program and its repurposing on the AES Web site with CME credit is supported by an educational grant from Eisai Inc.
Disclosure: It is the policy of the American Epilepsy Society that all faculty participating in continuing medical education activities are expected to disclose to the program audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. The American Epilepsy Society adheres to the ACCMEs Essential Areas and Policies regarding industry support of continuing medical education. Disclosure by faculty of commercial relationships, if any, and discussions of unlabeled or unapproved uses will be made.
H. Steve White, PhD has indicated that he receives consulting fees and fees for non-CME services directly from commercial interests or their agents from Johnson & Johnson. Dr. White has indicated that he does not intend to reference unlabeled/unapproved uses of drugs or products in his presentation.
Meir Bialer, PhD, MBA has indicated that he receives consulting fees from Desitin; Jazz Pharmaceuticals; Johnson & Johnson; Merck & Co., Inc.; and TEVA Pharmaceutical Industries Ltd. Dr. Bialer has indicated that he does not intend to reference unlabeled/unapproved uses of drugs or products in his presentation.
Gail D. Anderson, PhD has indicated that she receives consulting fees from Eisai Inc. and fees for non-CME services directly from commercial interests or their agents from UCB Pharma, Inc.
Disclaimer: Opinions expressed with regard to unapproved uses of products are solely those of the faculty and are not endorsed by the American Epilepsy Society or any manufacturers of pharmaceuticals.